Human cytochrome P450 epoxygenases: Variability in expression and role in inflammation-related disorders

Pharmacology and Therapeutics

Volumn 144, Issue 2, 2014, Pages 134-161

  Shahabi, Payman ^a   Siest, Gérard ^a   Meyer, Urs A ^b   Visvikis Siest, Sophie ^a,c  

^a UNIVERSITÉ DE LORRAINE   (France)

^b UNIVERSITY OF BASEL   (Switzerland)

^c CHU NANCY BRABOIS   (France)

Author keywords

Cytochrome P450; Epoxyeicosatrienoic acids; Epoxygenase; Inflammation; Variability

Indexed keywords

CELL NUCLEUS RECEPTOR; CYTOCHROME P450; CYTOCHROME P450 REDUCTASE; DNA; EPOXYICOSATRIENOIC ACID; HISTONE; MICRORNA; SEX HORMONE; XENOBIOTIC AGENT; ARACHIDONIC ACID; HEPATOCYTE NUCLEAR FACTOR 4; HNF4A PROTEIN, HUMAN; ICOSANOID; UNSPECIFIC MONOOXYGENASE;

AGE; BINDING SITE; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; DISEASES; DNA METHYLATION; ENVIRONMENTAL FACTOR; EPIGENETICS; GASTROINTESTINAL TRACT; GENDER; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEART PROTECTION; HISTONE MODIFICATION; HUMAN; INFLAMMATION; RESPIRATORY SYSTEM; REVIEW; SYSTEMIC DISEASE; TRANSCRIPTION REGULATION; UROGENITAL SYSTEM; VASCULAR BIOLOGY; CARDIOVASCULAR DISEASE; ENVIRONMENT; GENE EXPRESSION; GENETIC EPIGENESIS; LIVER; METABOLISM; PATHOPHYSIOLOGY; SEX DIFFERENCE; TRANSCRIPTION INITIATION;

AGE FACTORS; ARACHIDONIC ACID; ARYL HYDROCARBON HYDROXYLASES; CARDIOVASCULAR DISEASES; CYTOCHROME P-450 ENZYME SYSTEM; EICOSANOIDS; ENVIRONMENT; EPIGENESIS, GENETIC; GENE EXPRESSION; HEPATOCYTE NUCLEAR FACTOR 4; HUMANS; INFLAMMATION; LIVER; POLYMORPHISM, GENETIC; SEX FACTORS; TRANSCRIPTIONAL ACTIVATION;

EID: 84907906660     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2014.05.011     Document Type: Review

References (324)

1. B.D. Adams, H. Furneaux, and B.A. White The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines Mol Endocrinol 21 2007 1132 1147
2. V. Agrawal, N. Huang, and W.L. Miller Pharmacogenetics of P450 oxidoreductase: Effect of sequence variants on activities of CYP1A2 and CYP2C19 Pharmacogenet Genomics 18 2008 569 576
3. V. Agrawal, and W.L. Miller P450 oxidoreductase: Genotyping, expression, purification of recombinant protein, and activity assessments of wild-type and mutant protein Methods Mol Biol 987 2013 225 237
4. A.E. Aitken, and E.T. Morgan Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes Drug Metab Dispos 35 2007 1687 1693
5. A.E. Aitken, T.A. Richardson, and E.T. Morgan Regulation of drug-metabolizing enzymes and transporters in inflammation Annu Rev Pharmacol Toxicol 46 2006 123 149
6. S.H. Almal, and H. Padh Implications of gene copy-number variation in health and diseases J Hum Genet 57 2012 6 13
7. G.D. Anderson Pregnancy-induced changes in pharmacokinetics: A mechanistic-based approach Clin Pharmacokinet 44 2005 989 1008
8. A. Anwar-mohamed, B.N. Zordoky, M.E. Aboutabl, and A.O. El-Kadi Alteration of cardiac cytochrome P450-mediated arachidonic acid metabolism in response to lipopolysaccharide-induced acute systemic inflammation Pharmacolal Res 61 2010 410 418
9. C. Arnold, M. Markovic, K. Blossey, G. Wallukat, R. Fischer, and R. Dechend Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of {omega}-3 fatty acids J Biol Chem 285 2010 32720 32733
10. S.S. Auerbach, R. Ramsden, M.A. Stoner, C. Verlinde, C. Hassett, and C.J. Omiecinski Alternatively spliced isoforms of the human constitutive androstane receptor Nucleic Acids Res 31 2003 3194 3207
11. W. Baer-Dubowska, A. Majchrzak-Celińska, and M. Cichocki Pharmocoepigenetics: A new approach to predicting individual drug responses and targeting new drugs Pharmacol Rep 63 2011 293 304
12. D.P. Bartel MicroRNAs: Target recognition and regulatory functions Cell 136 2009 215 233
13. L. Becquemont, O. Chazouilleres, L. Serfaty, J.M. Poirier, F. Broly, and P. Jaillon Effect of interferon alpha-ribavirin biotherapy on cytochrome P450 1A2 and 2D6 N-acetyltransferase-2 activities in patients with chronic active hepatitis C Clin Pharmacol Ther 71 2002 488 495
14. C. Bertrand-Thiebault, L. Ferrari, O. Boutherin-Falson, M. Kockx, S. Desquand-Billiald, and J.M. Fichelle Cytochromes P450 are differently expressed in normal and varicose human saphenous veins: Linkage with varicosis Clin Exp Pharmacol Physiol 31 2004 295 301
15. Z. Bibi Role of cytochrome P450 in drug interactions Nutr Metab (Lond) 5 2008 27
16. S.C. Biddie Chromatin architecture and the regulation of nuclear receptor inducible transcription J Neuroendocrinol 23 2011 94 106
17. I. Bièche, C. Narjoz, T. Asselah, S. Vacher, P. Marcellin, and R. Lidereau Reverese transcriptase PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues Pharmacogenet Genomics 17 2007 731 742
18. A. Bird Perceptions of epigenetics Nature 447 2007 396 398
19. J.G. Blanco, P.L. Harrison, W.E. Evans, and M.V. Relling Human cytochrome P450 maximal activities in pediatric versus adult liver Drug Metab Dispos 28 2000 379 382
20. R. Bort, M.J. Gómez-Lechón, J.V. Castell, and R. Jover Role of hepatocyte nuclear factor 3 gamma in the expression of human CYP2C genes Arch Biochem Biophys 426 2004 63 72
21. A.H. Burstein, W.G. Reiss, E. Kantor, and G.D. Anderson Cytochrome P450 3A4 activity in premenopausal and postmenopausal women, based on 6-beta-hydroxycortisol:cortisol ratios Pharmacotherapy 18 1998 1271 1276
22. P. Caiafa, and M. Zampieri DNA methylation and chromatin structure: The puzzling CpG islands J Cell Biochem 94 2005 257 265
23. W.B. Campbell, and I. Fleming Epoxyeicosatrienoic acids and endothelium-dependent responses Pflugers Arch - Eur J Physiol 459 2010 881 895
24. W.B. Campbell, D. Gebremedhin, P.F. Pratt, and D.R. Harder Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors Circ Res 78 1996 415 423
25. J.H. Capdevila, and J.R. Falck Biochemical and molecular properties of the cytochrome P450arachidonic acid monooxygenases Prostaglandins Other Lipid Mediat 68-69 2002 325 344
26. J.H. Capdevila, J.R. Falck, and R.C. Harris Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase J Lipid Res 41 2000 163 181
27. G. Castaño, A. Burgueño, T. Fernández Gianotti, C.J. Pirola, and S. Sookoian The influence of common gene variants of the xenobiotic receptor (PXR) in genetic susceptibility to intrahepatic cholestasis of pregnancy Aliment Pharmacol Ther 31 2010 583 592
28. X. Chai, S. Zeng, and W. Xie Nuclear receptors PXR and CAR: Implications for drug metabolism regulation, pharmacogenomics and beyond Exp Opin Drug Metab Toxicol 9 2013 253 266
29. D. Chakravarti, V.J. LaMorte, M.C. Nelson, T. Nakajima, I.G. Schulman, and H. Juguilon Role of CBP/P300 in nuclear receptor signalling Nature 383 1996 99 103
30. K.R. Chaudhary, S.N. Batchu, and J.M. Seubert Cytochrome P450 enzymes and the heart IUBMB Life 61 2009 954 960
31. F. Chen, C. Chen, S. Yang, W. Gong, Y. Wang, and K. Cianflone Let-7b inhibits human cancer phenotype by targeting cytochrome P450 epoxygenase 2J2 PLoS One 7 2012 e39197
32. Y. Chen, S. Coulter, A.M. Jetten, and J.A. Goldstein Identification of human CYP2C8 as a retinoid-related orphan nuclear receptor target gene J Pharmacol Exp Ther 329 2009 192 201
33. Y. Chen, S.S. Ferguson, M. Negishi, and J.A. Goldstein Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter Mol Pharmacol 64 2003 316 324
34. Y. Chen, S.S. Ferguson, M. Negishi, and J.A. Goldstein Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor J Pharmacol Exp Ther 308 2004 495 501
35. Y. Chen, and J.A. Goldstein The transcriptional regulation of the human CYP2C genes Curr Drug Metab 10 2009 567 578
36. Y. Chen, G. Kissling, M. Negishi, and J.A. Goldstein The nuclear receptors constitutive androstane receptor and pregnane X receptor cross-talk with hepatic nuclear factor 4alpha to synergistically activate the human CYP2C9 promoter J Pharmacol Exp Ther 314 2005 1125 1133
37. X. Chen, L.Q. Pan, H. Naranmandura, S. Zeng, and S.Q. Chen Influence of various polymorphic variants of cytochrome P450 oxidoreductase (POR) on drug metabolic activity of CYP3A4 and CYP2B6 PLoS One 7 2012 e38495
38. Y.M. Choi, S. An, E.M. Lee, K. Kim, S.J. Choi, and J.S. Kim CYP1A1 is a target of miR-892a-mediated post-transcriptional repression Int J Oncol 41 2012 331 336
39. S.Y. Choi, K.H. Koh, and H. Jeong Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone Drug Metab Dispos 41 2013 263 269
40. H. Christensen, and M. Hermann Immunological response as a source to variability in drug metabolism and transport Front Pharmacol 3 2012 8
41. J.C. Chuang, and P.A. Jones Epigenetics and microRNAs Pediatr Res 61 2007 24R 29R
42. M.D. Coleman Human drug metabolism - An introduction ed. 2 2010 Wiley-Blackwell
43. D.F. Conrad, T.D. Andrews, N.P. Carter, M.E. Hurles, and J.K. Pritchard A high-resolution survey of deletion polymorphisms in the human genome Nat Genet 38 2006 75 81
44. M.M. Cotreau, L.L. von Moltke, and D.J. Greenblatt The influence of age and sex on the clearance of cytochrome P450 3A substrates Clin Pharmacokinet 44 2005 33 60
45. B.E. Daikh, J.M. Lasker, J.L. Raucy, and D.R. Koop Regio- and stereoselective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9 J Pharmacol Exp Ther 271 1994 1427 1433
46. E.P. Daskalopoulos, M.A. Lang, M. Marselos, F. Malliou, and M. Konstandi D-dopaminergic receptor-linked pathways: critical regulators of CYP3A, CYP2C, and CYP2D Mol Pharmacol 82 2012 668 678
47. E.P. Daskalopoulos, F. Malliou, G. Rentesi, M. Marselos, M.A. Lang, and M. Konstandi Stress is a critical player in CYP3A, CYP2C, and CYP2D regulation: Role of adrenergic receptor signaling pathways Am J Physiol Endocrinol Metab 303 2012 E40 E54
48. I. de Waziers, P.H. Cugnenc, C.S. Yang, J.P. Leroux, and P.H. Beaune Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues J Pharmacol Exp Ther 253 1990 387 394
49. L. del Senno, G.L. Aguiari, and R. Piva Dinucleotide repeat polymorphism in the human estrogen receptor (ESR) gene Hum Mol Genet 1 1992 354
50. R.R. Delongchamp, C. Velasco, S. Dial, and A.J. Harris Genome-wide estimation of gender differences in the gene expression human livers: Statistical design and analysis BMC Bioinformatics 6 Suppl. 2 2005 S13
51. T.C. Delozier, G.E. Kissling, S.J. Coulter, D. Dai, J.F. Foley, and J.A. Bradbury Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues Drug Metab Dispos 35 2007 682 688
52. Y. Deng, K.N. Theken, and C.R. Lee Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation J Mol Cell Cardiol 48 2010 331 341
53. M.S. Denison, and S.R. Nagy Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals Annu Rev Pharmacol Toxicol 43 2003 309 334
54. I.G. Denisov, T.M. Makris, S.G. Sligar, and I. Schlichting Structure and chemistry of cytochrome P450 Chem Rev 105 2005 2253 2277
55. A. Devendran, C.R. Uppugunduri, R. Sundaram, D.G. Shewade, K. Rajagopal, and A. Chandrasekaran Relative copy number variations of CYP2C19 in South Indian population Mol Biol Int 2012 2012 643856
56. D. Dhawan, and H. Padh Pharmacogenetics: Technologies to detect copy number variations Curr Opin Mol Ther 11 2009 670 680
57. X. Ding, and L.S. Kaminsky Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts Annu Rev Pharmacol Toxicol 43 2003 149 173
58. X. Ding, K. Lichti, I. Kim, F.J. Gonzalez, and J.L. Staudinger Regulation of constitutive androstane receptor and its target genes by fasting, cAMP, hepatocyte nuclear factor alpha, and the coactivator peroxisome proliferator-activated receptor gamma coactivator-1alpha J Biol Chem 281 2006 26540 26551
59. M. Dobrinas, J. Cornuz, B. Oneda, M. Kohler Serra, M. Puhl, and C.B. Eap Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility Clin Pharmacol Ther 90 2011 117 125
60. M. Dobrinas, J. Cornuz, L. Pedrido, and C.B. Eap Influence of cytochrome P450 oxidoreductase genetic polymorphisms on CYP1A2 activity and inducibility by smoking Pharmacogenet Genomics 22 2012 143 151
61. P. Dongiovanni, and L. Valenti Peroxisome proliferator-activated receptor genetic polymorphisms and nonalcoholic fatty liver disease: any role in disease susceptibility? PPAR Res 2013 2013 452061
62. L. Drocourt, J.C. Ourlin, J.M. Pascussi, P. Maurel, and M.J. Vilarem Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes J Biol Chem 277 2002 25125 25132
63. F. Dutheil, P. Beaune, and M.A. Loriot Xenobiotic metabolizing enzymes in the central nervous system: Contribution of cytochrome P450 enzymes in normal and pathological human brain Biochimie 90 2008 426 436
64. F. Dutheil, S. Dauchy, M. Diry, V. Sazdovitch, O. Cloarec, and L. Mellottée Xenobiotic-metabolizing enzymes and transporters in the normal human brain: Regional and cellular mapping as a basis for putative roles in cerebral function Drug Metab Dispos 37 2009 1528 1538
65. R.H. Elbekai, and A.O. El-Kadi Cytochrome P450 enzymes: Central players in cardiovascular health and disease Pharmacol Ther 112 2006 564 587
66. A.E. Enayetallah, R.A. French, M.S. Thibodeau, and D.F. Grant Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues J Histochem Cytochem 52 2004 447 454
67. K. Endo-Umeda, S. Uno, K. Fujimori, Y. Naito, K. Saito, and K. Yamagishi Differential expression and function of alternative splicing variants of human liver X receptorα Mol Pharmacol 81 2012 800 810
68. R. Feil, and M.F. Fraga Epigenetics and the environment: Emerging patterns and implications Nat Rev Genet 13 2012 97 109
69. J. Ferdin, T. Kunej, and G.A. Calin Non-coding RNAs: Identification of cancer-associated microRNAs by gene profiling Technol Cancer Res Treat 9 2010 123 138
70. S.S. Ferguson, Y. Chen, E.L. LeCluyse, M. Negishi, and J.A. Goldstein Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane X receptor, glucocorticoid receptor, and hepatic nuclear factor 4alpha Mol Pharmacol 68 2005 747 757
71. S.S. Ferguson, E.L. LeCluyse, M. Negishi, and J.A. Goldstein Regulation of human CYP2C9 by the constitutive androstane receptor: Discovery of a new distal binding site Mol Pharmacol 62 2002 737 746
72. B. Fisslthaler, R. Popp, L. Kiss, M. Potente, D.R. Harder, and I. Fleming Cytochrome P450 2C is an EDHF synthase in coronary arteries Nature 401 1999 493 497
73. J.C. Fleishaker, L.K. Pearson, P.G. Pearson, L.C. Wienkers, N.K. Hopkins, and G.R. Peters Hormonal effects on tirilazad clearance in women: Assessment of the role of CYP3A J Clin Pharmacol 39 1999 260 267
74. I. Fleming The cytochrome P450 pathway in angiogenesis and endothelial cell biology Cancer Metastasis Rev 30 2011 541 555
75. C.E. Flück, C. Nicolo, and A.V. Pandey Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450oxidoreductase Fundam Clin Pharmacol 21 2007 399 410
76. F. Franconi, S. Brunelleschi, L. Steardo, and V. Cuomo Gender differences in drug responses Pharmacol Res 55 2007 81 95
77. T. Fukami, M. Nakajima, H. Yamanaka, Y. Fukushima, H.L. McLeod, and T. Yokoi A novel duplication type of CYP2A6 gene in African-American population Drug Metab Dispos 35 2007 515 520
78. C. Gabay, and I. Kushner Acute-phase proteins and other systemic responses to inflammation N Engl J Med 340 1999 448 454
79. A. Gaedigk, D.W. Baker, R.A. Totah, R. Gaedigk, R.E. Pearce, and C.A. Vyhlidal Variability of CYP2J2 expression in human fetal tissues J Pharmacol Exp Ther 319 2006 523 532
80. A. Gaedigk, J. Hernandez, V. García-Solaesa, S. Sánchez, and M. Isidoro-García Detection and characterization of the CYP2D6∗9x2 gene duplication in two Spanish populations: Resolution of AmpliChip CYP450 test no-calls Pharmacogenomics 12 2011 1617 1622
81. A. Gaedigk, G.P. Twist, and J.S. Leeder CYP2D6, SULT1A1 and UGT2B17 copy number variation: Quantitative detection by multiplex PCR Pharmacogenomics 13 2012 91 111
82. M. Gandhi, F. Aweeka, R.M. Greenblatt, and T.F. Blaschke Sex differences in pharmacokinetics and pharmacodynamics Annu Rev Pharmacol Toxicol 44 2004 499 523
83. L. Gennari, D. Merlotti, V. De Paola, A. Calabrò, L. Becherini, and G. Martini Estrogen receptor gene polymorphisms and the genetics of osteoporosis: A huge review Am J Epidemiol 161 2005 307 320
84. M. Georges, W. Coppieters, and C. Charlier Polymorphic miRNA-mediated gene regulation: contribution to phenotypic variation and disease Curr Opin Genet Dev 17 2007 166 176
85. S. Gerbal-Chaloin, M. Daujat, J.M. Pascussi, L. Pichard-Garcia, M.J. Vilarem, and P. Maurel Transcriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and constitutive androstane receptor J Biol Chem 277 2002 209 217
86. S. Gerbal-Chaloin, J.M. Pascussi, L. Pichard-Garcia, M. Daujat, F. Waechter, and J.M. Fabre Induction of CYP2C genes in human hepatocytes in primary culture Drug Metab Dispos 29 2001 242 251
87. I. Gomez, C. Benyahia, J. Le Dall, C. Payré, L. Louedec, and G. Leséche Absence of inflammatory conditions in human varicose saphenous veins Inflamm Res 62 2013 299 308
88. J. Gong, Y. Tong, H.M. Zhang, K. Wang, T. Hu, and G. Shan Genome-wide identification of SNPs in microRNA genes and the SNP effects on microRNA target binding and biogenesis Hum Mutat 33 2012 254 263
89. J.C. Gorski, Z. Wang, B.D. Haehner-Daniels, S.A. Wrighton, and S.D. Hall The effect of hormone replacement therapy on CYP3A activity Clin Pharmacol Ther 68 2000 412 417
90. D.J. Greenblatt, R.I. Shader, K. Franke, D.S. MacLaughlin, B.J. Ransil, and J. Koch-Weser Kinetics of intravenous chlordiazepoxide: Sex differences in drug distribution Clin Pharmacol Ther 22 1997 893 903
91. G.J. Gross, and K. Nithipatikom Soluble epoxide hydrolase: A new target for cardioprotection Curr Opin Investig Drugs 10 2009 253 258
92. F.P. Guengerich Cytochrome P450s and other enzymes in drug metabolism and toxicity AAPS J 8 2006 E101 E111
93. S. Hägg, O. Spigset, and R. Dahlqvist Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers Br J Clin Pharmacol 51 2001 169 173
94. R.L. Haining, and M. Nichols-Haining Cytochrome P450-catalyzed pathways in human brain: Metabolism meets pharmacology or old drugs with new mechanism of action? Pharmacol Ther 113 2007 537 545
95. C. Handschin, and U.A. Meyer Induction of drug metabolism: The role of nuclear receptors Pharmacol Rev 55 2003 649 673
96. O. Hankinson The aryl hydrocarbon receptor complex Annu Rev Pharmacol Toxicol 35 1995 307 340
97. D.R. Harder, W.B. Campbell, and R.J. Roman Role of cytochrome P-450 enzymes and metabolites of arachidonic acid in the control of vascular tone J Vasc Res 32 1995 79 92
98. R.Z. Harris, S.M. Tsunoda, P. Mroczkowski, H. Wong, and L.Z. Benet The effects of menopause and hormone replacement therapies on prednisolone and erythromycin pharmacokinetics Clin Pharmacol Ther 59 1996 429 435
99. D.G. Harrison, T.J. Guzik, H.E. Lob, M.S. Madhur, P.J. Marvar, and S.R. Thabet Inflammation, immunity, and hypertension Hypertension 57 2011 132 140
100. S.N. Hart, and X.B. Zhong P450 oxidoreductase: Genetic polymorphisms and implications for drug metabolism and toxicity Exp Opin Drug Metab Toxicol 4 2008 439 452
101. S. Hata, Y. Miki, F. Fujishima, R. Sato, A. Okaue, and K. Abe Cytochrome 3A and 2E1 in human liver tissue: Individual variations among normal Japanese subjects Life Sci 86 2010 393 401
102. Y. He, J.M. Hoskins, and H.L. McLeod Copy number variants in pharmacogenetic genes Trends Mol Med 17 2011 244 251
103. S.J. Hebbring, A.A. Adjei, J.L. Baer, G.D. Jenkins, J. Zhang, and J.M. Cunningham Human SULT1A1 gene: Copy number differences and functional implications Hum Mol Genet 16 2007 463 470
104. S. Helmig, B. Hadzaad, J. Döhrel, and J. Schneider Relative quantification of cytochrome P450 1B1 gene expression in peripheral leukocytes using lightcycler Cancer Genom Proteomics 6 2009 13 17
105. N.A. Helsby, and K.E. Burns Molecular mechanisms of genetic variation and transcriptional regulation of CYP2C19 Front Genet 3 2012 206
106. J.G. Hengstler, and H.M. Bolt Failure in drug development: The role of inhibition and induction of cytochrome P450 enzymes Arch Toxicol 82 2008 665 666
107. N.J. Hewitt, E.L. Lecluyse, and S.S. Ferguson Induction of hepatic cytochrome P450 enzymes: Methods, mechanisms, recommendations, and in vitro-in vivo correlations Xenobiotica 37 2007 1196 1224
108. R.N. Hines Ontogeny of human hepatic cytochromes P450 J Biochem Mol Toxicol 21 2007 169 175
109. R.N. Hines The ontogeny of drug metabolism enzymes and implications for adverse drug events Pharmacol Ther 118 2008 250 267
110. L.S. Hodge, and T.S. Tracy Alterations in drug disposition during pregnancy: Implications for drug therapy Exp Opin Drug Metab Toxicol 3 2007 557 571
111. M.G. Holloway, G.D. Miles, A.A. Dombkowski, and D.J. Waxman Liver-specific hepatocyte nuclear factor-4alpha deficiency: Greater impact on gene expression in male than in female mouse liver Mol Endocrinol 22 2008 1274 1286
112. P. Honkakoski, and M. Negishi Regulation of cytochrome P450 (CYP) genes by nuclear receptors Biochem J 347 2000 321 337
113. H. Huang, J. Chen, T. Lin, T. Wang, Y. Tang, and Y. Dong Epoxyeicosatrienoic acids - novel mechanism and pharmacological therapy of chronic renocardiac syndrome Med Hypotheses 76 2011 550 552
114. R.S. Huang, P. Chen, S. Wisel, S. Duan, W. Zhang, and E.H. Cook Population-specific GSTM1 copy number variation Hum Mol Genet 18 2009 366 372
115. W.W. Hwang-Verslues, and F.M. Sladek HNF4α - role in drug metabolism and potential drug target? Curr Opin Pharmacol 10 2010 698 705
116. G.C. Ibeanu, and J.A. Goldstein Transcriptional regulation of human CYP2C genes: Functional comparison of CYP2C9 and CYP2C18 promoter regions Biochemistry (Mosc) 34 1995 8028 8036
117. S. Ikeda, K. Kurose, H. Jinno, K. Sai, S. Ozawa, and R. Hasegawa Functional analysis of four naturally occurring variants of human constitutive androstane receptor Mol Genet Metab 86 2005 314 319
118. J.D. Imig Epoxygenase metabolites. Epithelial and vascular actions Mol Biotechnol 16 2000 233 251
119. J.D. Imig Epoxides and soluble epoxide hydrolase in cardiovascular physiology Physiol Rev 92 2012 101 130
120. J.D. Imig, and B.D. Hammock Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases Nat Rev Drug Discov 8 2009 794 805
121. M. Ingelman-Sundberg, I. Johansson, H. Yin, Y. Terelius, E. Eliasson, and P. Clot Ethanol-inducible cytochrome P4502E1: Genetic polymorphism, regulation, and possible role in the etiology of alcohol-induced liver disease Alcohol 10 1993 447 452
122. M. Ingelman-Sundberg, S.C. Sim, A. Gomez, and C. Rodriguez-Antona Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects Pharmacol Ther 116 2007 496 526
123. J. Isensee, and P. Ruiz Noppinger Sexually dimorphic gene expression in mammalian somatic tissue Gend Med 4 Suppl. B 2007 S75 S95
124. M. Ivanov, M. Kacevska, and M. Ingelman-Sundberg Epigenomics and interindividual differences in drug response Clin Pharmacol Ther 92 2012 727 736
125. C.M. Jenkins, A. Cedars, and R.W. Gross Eicosanoid signalling pathways in the heart Cardiovasc Res 82 2009 240 249
126. H. Jeong Altered drug metabolism during pregnancy: Hormonal regulation of drug-metabolizing enzymes Exp Opin Drug Metab Toxicol 6 2010 689 699
127. H. Jiang, G.D. Anderson, and J.C. McGiff Red blood cells (RBCs), epoxyeicosatrienoic acids (EETs) and adenosine triphosphate (ATP) Pharmacol Rep 62 2010 468 474
128. H. Jiang, J.C. McGiff, J. Quilley, D. Sacerdoti, L.M. Reddy, and J.R. Falck Identification of 5,6-trans-epoxyeicosatrienoic acid in the phospholipids of red blood cells J Biol Chem 279 2004 36412 36418
129. H. Jiang, J. Quilley, L.M. Reddy, J.R. Falck, P.Y. Wong, and J.C. McGiff Red blood cells: Reservoirs of cis- and trans-epoxyeicosatrienoic acids Prostaglandins Other Lipid Mediat 75 2005 65 78
130. H. Jiang, A.G. Zhu, M. Mamczur, J.R. Falck, K.M. Lerea, and J.C. McGiff Stimulation of rat erythrocyte P2X7 receptor induces the release of epoxyeicosatrienoic acids Br J Pharmacol 151 2007 1033 1040
131. H. Jinno, T. Tanaka-Kagawa, N. Hanioka, S. Ishida, M. Saeki, and A. Soyama Identification of novel alternative splice variants of human constitutive androstane receptor and characterization of their expression in the liver Mol Pharmacol 65 2004 496 502
132. I. Johansson, and M. Ingelman-Sundberg CNVs of human genes and their implication in pharmacogenetics Cytogenet Genome Res 123 2008 195 204
133. R. Jover, R. Bort, M.J. Gomez-Lechon, and J.V. Castell Re-expression of C/EBP alpha induces CYP2B6, CYP2C9 and CYP2D6 genes in HepG2 cells FEBS Lett 431 1998 227 230
134. R. Jover, M. Moya, and M.J. Gomez-Lechon Transcriptional regulation of cytochrome p450 genes by the nuclear receptor hepatocyte nuclear factor 4-alpha Curr Drug Metab 10 2009 508 519
135. M. Kacevska, M. Ivanov, and M. Ingelman-Sundberg Epigenetic-dependent regulation of drug transport and metabolism: An update Pharmacogenomics 13 2012 1373 1385
136. A.S. Kalgutkar, R.S. Obach, and T.S. Maurer Mechanism-based inactivation of cytochrome P450 enzymes: Chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions Curr Drug Metab 8 2007 407 447
137. L.S. Kaminsky, and Q.Y. Zhang The small intestine as a xenobiotic-metabolizing organ Drug Metab Dispos 31 2003 1520 1525
138. Y. Kamiyama, T. Matsubara, K. Yoshinari, K. Nagata, H. Kamimura, and Y. Yamazoe Role of human hepatocyte nuclear factor 4alpha in the expression of drug-metabolizing enzymes and transporters in human hepatocytes assessed by use of small interfering RNA Drug Metab Pharmacokinet 22 2007 287 298
139. A. Karara, E. Dishman, H. Jacobson, J.R. Falck, and J.H. Capdevila Arachidonic acid epoxygenase. Stereochemical analysis of the endogenous epoxyeicosatrienoic acids of human kidney cortex FEBS Lett 268 1990 227 230
140. A.D. Kashuba, and A.N. Nafziger Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs Clin Pharmacokinet 34 1998 203 218
141. R. Kaspera, and R.A. Totah Epoxyeicosatrienoic acids: formation, metabolism and potential role in tissue physiology and pathophysiology Exp Opin Drug Metab Toxicol 5 2009 757 771
142. S. Kato, A. Yokoyama, and R. Fujiki Nuclear receptor coregulators merge transcriptional coregulation with epigenetic regulation Trends Biochem Sci 36 2011 272 281
143. H. Kawakami, S. Ohtsuki, J. Kamiie, T. Suzuki, T. Abe, and T. Terasaki Simultaneous absolute quantification of 11 cytochrome P450 isoforms in human liver microsomes by liquid chromatography tandem mass spectrometry with in silico target peptide selection J Pharm Sci 100 2011 341 352
144. S. Kawashima, K. Kobayashi, K. Takama, T. Higuchi, T. Furihata, and M. Hosokawa Involvement of hepatocyte nuclear factor 4alpha in the different expression level between CYP2C9 and CYP2C19 in the human liver Drug Metab Dispos 34 2006 1012 1018
145. S. Ke, A.B. Rabson, J.F. Germino, M.A. Gallo, and Y. Tian Mechanism of suppression of cytochrome P-450 1A1 expression by tumor necrosis factor-alpha and lipopolysaccharide J Biol Chem 276 2001 39638 39644
146. G.L. Kearns, S.M. Abdel-Rahman, S.W. Alander, D.L. Blowey, J.S. Leeder, and R.E. Kauffman Developmental pharmacology - Drug disposition, action, and therapy in infants and children N Engl J Med 349 2003 1157 1167
147. M. Kennedy Hormonal regulation of hepatic drug-metabolizing enzyme activity during adolescence Clin Pharmacol Ther 84 2008 662 673
148. S.C. Khojasteh, S. Prabhu, J.R. Kenny, J.S. Halladay, and A.Y. Lu Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: A re-evaluation of P450 isoform selectivity Eur J Drug Metab Pharmacokinet 36 2011 1 16
149. J.M. Kidd, G.M. Cooper, W.F. Donahue, H.S. Hayden, N. Sampas, and T. Graves Mapping and sequencing of structural variation from eight human genomes Nature 453 2008 56 64
150. V.N. Kim, J. Han, and M.C. Siomi Biogenesis of small RNAs in animals Nat Rev Mol Cell Biol 10 2009 126 139
151. M.T. Kinirons, and M.S. O'Mahony Drug metabolism and ageing Br J Clin Pharmacol 57 2004 540 544
152. C.D. Klaassen, H. Lu, and J.Y. Cui Epigenetic regulation of drug processing genes Toxicol Mech Methods 21 2011 312 324
153. D.A. Kleinjan, and V. van Heyningen Long-range control of gene expression: emerging mechanisms and disruption in disease Am J Hum Genet 76 2005 8 32
154. I. Koch, R. Weil, R. Wolbold, J. Brockmöller, E. Hustert, and O. Burk Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA Drug Metab Dispos 30 2002 1108 1114
155. A. Konkel, and W.H. Schunck Role of cytochrome P450 enzymes in the bioactivation of polyunsaturated fatty acids Biochim Biophys Acta 1814 2011 210 222
156. T. Kouzarides Chromatin modifications and their function Cell 128 2007 693 705
157. S. Koyano, K. Kurose, Y. Saito, S. Ozawa, R. Hasegawa, and K. Komamura Functional characterization of four naturally occurring variants of human pregnane X receptor (PXR): one variant causes dramatic loss of both DNA binding activity and the transactivation of the CYP3A4 promoter/enhancer region Drug Metab Dispos 32 2004 149 154
158. F.A. Kuehl Jr., and R.W. Egan Prostaglandins, arachidonic acid, and inflammation Science 210 1980 978 984
159. T. Kunej, I. Godnic, J. Ferdin, S. Horvat, P. Dovc, and G.A. Calin Epigenetic regulation of microRNAs in cancer: An integrated review of literature Mutat Res 717 2011 77 84
160. X.S. Lai, L.P. Yang, X.T. Li, J.P. Liu, Z.W. Zhou, and S.F. Zhou Human CYP2C8: Structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms Curr Drug Metab 10 2009 1009 1047
161. K. Laine, G. Tybring, and L. Bertilsson No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects Clin Pharmacol Ther 68 2000 151 159
162. J.K. Lamba Pharmacogenetics of the constitutive androstane receptor Pharmacogenomics 9 2008 71 83
163. J. Lamba, V. Lamba, and E. Schuetz Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics Curr Drug Metab 6 2005 369 383
164. J.K. Lamba, V. Lamba, K. Yasuda, Y.S. Lin, M. Assem, and E. Thompson Expression of constitutive androstane receptor splice variants in human tissues and their functional consequences J Pharmacol Exp Ther 311 2004 811 821
165. V. Lamba, J. Lamba, K. Yasuda, S. Strom, J. Davila, and M.L. Hancock Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression J Pharmacol Exp Ther 307 2003 906 922
166. F. Läpple, O. von Richter, M.F. Fromm, T. Richter, K.P. Thon, and H. Wisser Differential expression and function of CYP2c isoforms in human intestine and liver Pharmacogenetics 13 2003 565 575
167. J. Leclerc, G. Tournel, E. Courcot-Ngoubo Ngangue, N. Pottier, J.J. Lafitte, and S. Jaillard Profiling gene expression of whole cytochrome P450 superfamily in human bronchial and peripheral lungtissues: Differential expression in non-small cell lung cancers Biochimie 92 2010 292 306
168. S.S. Lee, E.Y. Cha, H.J. Jung, J.H. Shon, E.Y. Kim, and C.W. Yeo Genetic polymorphism of hepatocyte nuclear factor-4alpha influences human cytochrome P450 2D6 activity Hepatology 48 2008 635 645
169. T. Li, and J.Y. Chiang Rifampicin induction of CYP3A4 requires pregnane X receptor cross talk with hepatocyte nuclear factor 4alpha and coactivators, and suppression of small heterodimer partner gene expression Drug Metab Dispos 34 2006 756 764
170. P. Libby Inflammation in atherosclerosis Nature 420 2002 868 874
171. J.H. Lin, and A.Y. Lu Interindividual variability in inhibition and induction of cytochrome P450 enzymes Annu Rev Pharmacol Toxicol 41 2001 535 567
172. D.M. Lonard, R.B. Lanz, and B.W. O'Malley Nuclear receptor coregulators and human disease Endocr Rev 28 2007 575 587
173. M. Lu, Q. Zhang, M. Deng, J. Miao, Y. Guo, W. Gao, and Q. Cui An analysis of human microRNA and disease associations PLoS One 3 2008 e3420
174. A. Madan, R.A. Graham, K.M. Carroll, D.R. Mudra, L.A. Burton, and L.A. Krueger Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes Drug Metab Dispos 31 2003 421 431
175. J.M. Maglich, C.M. Stoltz, B. Goodwin, D. Hawkins-Brown, J.T. Moore, and S.A. Kliewer Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification Mol Pharmacol 62 2002 638 646
176. M. Makishima, T.T. Lu, W. Xie, G.K. Whitfield, H. Domoto, and R.M. Evans Vitamin D receptor as an intestinal bile acid sensor Science 296 2002 1313 1316
177. N.Y. Marden, E. Fiala-Beer, S.H. Xiang, and M. Murray Role of activator protein-1 in the down-regulation of the human CYP2J2 gene in hypoxia Biochem J 373 2003 669 680
178. N.Y. Marden, and M. Murray Characterization of a c-Jun-responsive module in the 5′-flank of the human CYP2J2 gene that regulates transactivation Biochem J 391 2005 631 640
179. C.C. Marohnic, S.P. Panda, K. McCammon, J. Rueff, B.S. Masters, and M. Kranendonk Human cytochrome P450 oxidoreductase deficiency caused by the Y181D mutation: Molecular consequences and rescue of defect Drug Metab Dispos 38 2010 332 340
180. S. Martis, H. Mei, R. Vijzelaar, L. Edelmann, R.J. Desnick, and S.A. Scott Multi-ethnic cytochrome-P450 copy number profiling: Novel pharmacogenetic alleles and mechanism of copy number variation formation Pharmacogenomics J 2012 (Epub ahead of print)
181. I. Mateo Leach, P. van der Harst, and R.A. de Boer Pharmacoepigenetics in heart failure Curr Heart Fail Rep 7 2010 83 90
182. J.C. Mathers, G. Strathdee, and C.L. Relton Induction of epigenetic alterations by dietary and other environmental factors Adv Genet 71 2010 3 39
183. A.E. May, H. Langer, P. Seizer, B. Bigalke, S. Lindemann, and M. Gawaz Platelet-leukocyte interactions in inflammation and atherothrombosis Semin Thromb Hemost 33 2007 123 127
184. J.A. McKay, and J.C. Mathers Diet induced epigenetic changes and their implications for health Acta Physiol 202 2011 103 118
185. M. Medhora, J. Daniels, K. Mundey, B. Fisslthaler, R. Busse, and E.R. Jacobs Epoxygenase-driven angiogenesis in human lung microvascular endothelial cells Am J Physiol Heart Circ Physiol 284 2003 H215 H224
186. M.C. Meyer, A.B. Straughn, R.M. Mhatre, V.P. Shah, M.L. Chen, and R.L. Williams Variability in the bioavailability of phenytoin capsules in males and females Pharm Res 18 2001 394 397
187. V. Michaud, M. Frappier, M.C. Dumas, and J. Turgeon Metabolic activity and mRNA levels of human cardiac CYP450s involved in drug metabolism PLoS One 5 2010 e15666
188. S.L. Miksys, and R.F. Tyndale Drug-metabolizing cytochrome P450s in the brain J Psychiatry Neurosci 27 2002 406 415
189. P.J. Mishra, and J.R. Bertino MicroRNA polymorphisms: The future of pharmacogenomics, molecular epidemiology and individualized medicine Pharmacogenomics 10 2009 399 416
190. S.J. Mitchell, A.E. Kane, and S.N. Hilmer Age-related changes in the hepatic pharmacology and toxicology of paracetamol Curr Geront Geriatr Res 2011 2011 624156
191. T. Mohri, M. Nakajima, T. Fukami, M. Takamiya, Y. Aoki, and T. Yokoi Human CYP2E1 is regulated by miR-378 Biochem Pharmacol 79 2010 1045 1052
192. T. Mohri, M. Nakajima, S. Takagi, S. Komagata, and T. Yokoi MicroRNA regulates human vitamin D receptor Int J Cancer 125 2009 1328 1333
193. D.D. Moore, S. Kato, W. Xie, D.J. Mangelsdorf, D.R. Schmidt, and R. Xiao International Union of Pharmacology. LXII. The NR1H and NR1I receptors: Constitutive androstane receptor, pregnene X receptor, farnesoid X receptor alpha, farnesoid X receptor beta, liver X receptor alpha, liver X receptor beta, and vitamin D receptor Pharmacol Rev 58 2006 742 759
194. E.T. Morgan Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics Clin Pharmacol Ther 85 2009 434 438
195. C.P. Morgan, and T.L. Bale Sex differences in microRNA regulation of gene expression: No smoke, just miRs Biol Sex Differ 3 2012 22
196. D. Moutinho, C.C. Marohnic, S.P. Panda, J. Rueff, B.S. Masters, and M. Kranendonk Altered human CYP3A4 activity caused by Antley-Bixler syndrome-related variants of NADPH-cytochrome P450 oxidoreductase measured in a robust in vitro system Drug Metab Dispos 40 2012 754 760
197. R. Müllenbach, S.N. Weber, and F. Lammert Nuclear receptor variants in liver disease J Lipids 2012 2012 934707
198. M. Murray Altered CYP expression and function in response to dietary factors: Potential roles in disease pathogenesis Curr Drug Metab 7 2006 67 81
199. M. Murray Role of signalling systems in the effects of dietary factors on the expression of mammalian CYPs Expert Opin Drug Metab Toxicol 3 2007 185 196
200. J. Mwinyi, I. Cavaco, R.S. Pedersen, A. Persson, S. Burkhardt, and S. Mkrtchian Regulation of CYP2C19 expression by estrogen receptor α: Implications for estrogen-dependent inhibition of drug metabolism Mol Pharmacol 78 2010 886 894
201. J. Mwinyi, Y. Hofmann, R.S. Pedersen, J. Nekvindová, I. Cavaco, and S. Mkrtchian The transcription factor GATA-4 regulates cytochrome P4502C19 gene expression Life Sci 86 2010 699 706
202. M. Nakajima, and T. Yokoi MicroRNAs from biology to future pharmacotherapy: Regulation of cytochrome P450s and nuclear receptors Pharmacol Ther 131 2011 330 337
203. H. Nakamura, H. Nakasa, I. Ishii, N. Ariyoshi, T. Igarashi, and S. Ohmori Effects of endogenous steroids on CYP3A4-mediated drug metabolism by human liver microsomes Drug Metab Dispos 30 2002 534 540
204. K. Nakayama, T. Nitto, T. Inoue, and K. Node Expression of the cytochrome P450 epoxygenase CYP2J2 in human monocytic leukocytes Life Sci 83 2008 339 345
205. S.B. Naraharisetti, Y.S. Lin, M.J. Rieder, K.D. Marciante, B.M. Psaty, and K.E. Thummel Human liver expression of CYP2C8: Gender, age, and genotype effects Drug Metab Dispos 38 2010 889 893
206. P. Neugebauer, M. Goldbergová-Pávková, P. Kala, O. Bocek, P. Jerábek, and M. Poloczek Nuclear receptors gene polymorphisms and risk of restenosis and clinical events following coronary stenting Vnitr Lek 55 2009 1135 1140
207. G.H. Ni, J.F. Chen, X.P. Chen, and T.L. Yang Soluble epoxide hydrolase: A promising therapeutic target for cardiovascular diseases Pharmazie 66 2011 153 157
208. O. Niemelä, S. Parkkila, R.O. Juvonen, K. Viitala, H.V. Gelboin, and M. Pasanen Cytochromes P450 2A6, 2E1, and 3A and production of protein-aldehyde adducts in the liver of patients with alcoholic and non-alcoholic liver diseases J Hepatol 33 2000 893 901
209. M. Nishimura, H. Yaguti, H. Yoshitsugu, S. Naito, and T. Satoh Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR Yakugaku Zasshi 123 2003 369 375
210. K. Node, Y. Huo, X. Ruan, B. Yang, M. Spiecker, and K. Ley Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids Science 285 1999 1276 1279
211. S. Norwood, J. Liao, B.D. Hammock, and G.Y. Yang Epoxyeicosatrienoic acids and soluble epoxide hydrolase: potential therapeutic targets for inflammation and its induced carcinogenesis Am J Transl Res 2 2010 447 457
212. S. Ohtsuki, O. Schaefer, H. Kawakami, T. Inoue, S. Liehner, and A. Saito Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: Comparison with mRNA levels and activities Drug Metab Dispos 40 2012 83 92
213. E.H. Oliw Oxygenation of polysaturated fatty acids by cytochrome P450 monoxygenases Prog Lipid Res 33 1994 329 354
214. S.T. Orr, S.L. Ripp, T.E. Ballard, J.L. Henderson, D.O. Scott, and R.S. Obach Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: Structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks J Med Chem 55 2012 4896 4933
215. K. Ouahchi, N. Lindeman, and C. Lee Copy number variants and pharmacogenomics Pharmacogenomics 7 2006 25 29
216. M.F. Paine, H.L. Hart, S.S. Ludington, R.L. Haining, A.E. Rettie, and D.C. Zeldin The human intestinal cytochrome P450 "pie" Drug Metab Dispos 34 2006 880 886
217. S. Palovaara, O. Pelkonen, J. Uusitalo, S. Lundgren, and K. Laine Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation Clin Pharmacol Ther 74 2003 326 333
218. Y.Z. Pan, W. Gao, and A.M. Yu MicroRNAs regulate CYP3A4 expression via direct and indirect targeting Drug Metab Dispos 37 2009 2112 2117
219. A.V. Pandey, and C.E. Flück NADPH P450 oxidoreductase: Structure, function, and pathology of diseases Pharmacol Ther 138 2013 229 254
220. D.P. Pandey, and D. Picard Multidirectional interplay between nuclear receptors and microRNAs Curr Opin Pharmacol 10 2010 637 642
221. B.K. Park Cytochrome P450 enzymes in the heart Lancet 355 2000 945 946
222. A. Parkinson, D.R. Mudra, C. Johnson, A. Dwyer, and K.M. Carroll The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes Toxicol Appl Pharmacol 199 2004 193 209
223. M. Pasanen, Z. Rannala, A. Tooming, E.A. Sotaniemi, O. Pelkonen, and A. Rautio Hepatitis A impairs the function of human hepatic CYP2A6 in vivo Toxicology 123 1997 177 184
224. J.M. Pascussi, L. Drocourt, J.M. Fabre, P. Maurel, and M.J. Vilarem Dexamethasone induces pregnane X receptor and retinoid X receptor-alpha expression in human hepatocytes: Synergistic increase of CYP3A4 induction by pregnane X receptor activators Mol Pharmacol 58 2000 361 372
225. J.M. Pascussi, S. Gerbal-Chaloin, C. Duret, M. Daujat-Chavanieu, M.J. Vilarem, and P. Maurel The tangle of nuclear receptors that controls xenobiotic metabolism and transport: Crosstalk and consequences Annu Rev Pharmacol Toxicol 48 2008 1 32
226. J.M. Pascussi, S. Gerbal-Chaloin, J.M. Fabre, P. Maurel, and M.J. Vilarem Dexamethasone enhances constitutive androstane receptor expression in human hepatocytes: Consequences on cytochrome P450 gene regulation Mol Pharmacol 58 2000 1441 1450
227. P. Pavek, M. Ceckova, and F. Staud Variation of drug kinetics in pregnancy Curr Drug Metab 10 2009 520 529
228. P. Pavek, and Z. Dvorak Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues Curr Drug Metab 9 2008 129 143
229. O. Pelkonen, M. Turpeinen, J. Hakkola, P. Honkakoski, J. Hukkanen, and H. Raunio Inhibition and induction of human cytochrome P450 enzymes: current status Arch Toxicol 82 2008 667 715
230. S.L. Pfister, K.M. Gauthier, and W.B. Campbell Vascular pharmacology of epoxyeicosatrienoic acids Adv Pharmacol 60 2010 27 59
231. S. Pillarisetti, and I. Khanna Targeting soluble epoxide hydrolase for inflammation and pain - An overview of pharmacology and the inhibitors Inflamm Allergy-Drug Targets 11 2012 143 158
232. B.G. Pollock, M. Wylie, J.A. Stack, D.A. Sorisio, D.S. Thompson, and M.A. Kirshner Inhibition of caffeine metabolism by estrogen replacement therapy in postmenopausal women J Clin Pharmacol 39 1999 936 940
233. S. Prasad, J. Ravindran, and B.B. Aggarwal NF-kappaB and cancer: How intimate is this relationship Mol Cell Biochem 336 2010 25 37
234. S. Preissner, K. Kroll, M. Dunkel, C. Senger, G. Goldsobel, and D. Kuzman SuperCYP: A comprehensive database on cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions Nucleic Acids Res 38 2010 D237 D243
235. A. Ramamoorthy, and T.C. Skaar Gene copy number variations: It is important to determine which allele is affected Pharmacogenomics 12 2011 299 301
236. M. Ramsjö, E. Aklillu, L. Bohman, M. Ingelman-Sundberg, H.K. Roh, and L. Bertilsson CYP2C19 activity comparison between Swedes and Koreans: Effect of genotype, sex, oral contraceptive use, and smoking Eur J Clin Pharmacol 66 2010 871 877
237. J.L. Raucy, L. Mueller, K. Duan, S.W. Allen, S. Strom, and J.M. Lasker Expression and induction of CYP2CP450 enzymes in primary cultures of human hepatocytes J Pharmacol Exp Ther 302 2002 475 482
238. R. Redon, S. Ishikawa, K.R. Fitch, L. Feuk, G.H. Perry, and T.D. Andrews Global variation in copy number in the human genome Nature 444 2006 444 454
239. S. Rendic, and F.P. Guengerich Update information on drug metabolism systems - 2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters Curr Drug Metab 11 2010 4 84
240. S. Rendic, and F.P. Guengerich Summary of information on the effects of ionizing and non-ionizing radiation on cytochrome P450 and other drug metabolizing enzymes and transporters Curr Drug Metab 13 2012 787 814
241. C. Rodríguez-Antona, M.T. Donato, E. Pareja, M.J. Gómez-Lechón, and J.V. Castell Cytochrome P-450 mRNA expression in human liver and its relationship with enzyme activity Arch Biochem Biophys 393 2001 308 315
242. C. Rodriguez-Antona, A. Gomez, M. Karlgren, S.C. Sim, and M. Ingelman-Sundberg Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment Hum Genet 127 2010 1 17
243. R.J. Roman P-450 Metabolites of arachidonic acid in the control of cardiovascular function Physiol Rev 82 2002 131 185
244. H.E. Rugstad, O. Hundal, I. Holme, O.B. Herland, G. Husby, and K.E. Giercksky Piroxicam and naproxen plasma concentrations in patients with osteoarthritis: Relation to age, sex, efficacy and adverse events Clin Rheumatol 5 1986 389 398
245. T. Sakuma, Y. Kawasaki, K. Jarukamjorn, and N. Nemoto Sex differences of drug metabolizing enzyme: Female predominant expression of human and mouse cytochrome P450 3A isoenzymes 55 2009 325 337
246. F. Sato, S. Tsuchiya, S.J. Meltzer, and K. Shimizu MicroRNAs and epigenetics FEBS J 278 2011 1598 1609
247. U. Satyanarayana Chakradhara Rao, A. Devendran, K. Satyamoorthy, D.G. Shewade, R. Krishnamoorthy, and A. Chandrasekaran Functional characterization of promoter region polymorphisms of human CYP2C19 gene Mol Biol Rep 38 2011 4171 4179
248. R.S. Savkur, Y. Wu, K.S. Bramlett, M. Wang, S. Yao, and D. Perkins Alternative splicing within the ligand binding domain of the human constitutive androstane receptor Mol Genet Metab 80 2003 216 226
249. M.J. Scandlyn, E.C. Stuart, and R.J. Rosengren Sex-specific differences in CYP450 isoforms in humans Expert Opin Drug Metab Toxicol 4 2008 413 424
250. D.L. Schmucker, K.W. Woodhouse, R.K. Wang, H. Wynne, O.F. James, and M. McManus Effects of age and gender on in vitro properties of human liver microsomal monooxygenases Clin Pharmacol Ther 48 1990 365 374
251. E.L. Schubert, M.K. Lee, B. Newman, and M.C. King Single nucleotide polymorphisms (SNPs) in the estrogen receptor gene and breast cancer susceptibility J Steroid Biochem Mol Biol 71 1999 21 27
252. G. Sethi, B. Sung, and B.B. Aggarwal Nuclear factor-kappaB activation: From bench to bedside Exp Biol Med (Maywood) 233 2008 21 31
253. P. Shahabi, G. Siest, and S. Visvikis-Siest Influence of inflammation on cardiovascular protective effects of cytochrome P450 epoxygenase-derived epoxyeicosatrienoic Acids Drug Metab Rev 46 2014 33 56
254. T. Shimada, H. Yamazaki, M. Mimura, Y. Inui, and F.P. Guengerich Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians J Pharmacol Exp Ther 270 1994 414 423
255. M. Shiraishi, A.J. Oates, and T. Sekiya An overview of the analysis of DNA methylation in mammalian genomes Biol Chem 383 2002 893 906
256. G. Siest, E. Jeannesson, J.B. Marteau, A. Samara, M. Pfister, and S. Visvikis-Siest Drug metabolizing enzymes and transporters mRNA in peripheral blood mononuclear cells of healthy subjects: Biological variations and importance of pre-analytical steps Curr Drug Metab 10 2009 410 419
257. A. Silahtaroglu, and J. Stenvang MicroRNAs, epigenetics and disease Essays Biochem 48 2010 165 185
258. S.C. Sim, and M. Ingelman-Sundberg The human cytochrome P450 (CYP) allele nomenclature website: A peer-reviewed database of CYP variants and their associated effects Hum Genomics 4 2010 278 281
259. S.C. Sim, M. Kacevska, and M. Ingelman-Sundberg Pharmacogenomics of drug-metabolizing enzymes: A recent update on clinical implications and endogenous effects Pharmacogenomics J 13 2013 1 11
260. O.P. Soldin, S.H. Chung, and D.R. Mattison Sex differences in drug disposition J Biomed Biotechnol 2011 2011 187103
261. M. Somel, P. Khaitovich, S. Bahn, S. Pääbo, and M. Lachmann Gene expression becomes heterogeneous with age Curr Biol 16 2006 R359 R360
262. E.A. Sotaniemi, A.J. Arranto, O. Pelkonen, and M. Pasanen Age and cytochrome P450-linked drug metabolism in humans: An analysis of 226 subjects with equal histopathologic conditions Clin Pharmacol Ther 61 1997 331 339
263. A.A. Spector Arachidonic acid cytochrome P450 epoxygenase pathway J Lipid Res 50 Suppl. 2009 S52 S56
264. A.A. Spector, and A.W. Norris Action of epoxyeicosatrienoic acids on cellular function Am J Physiol Cell Physiol 292 2007 C996 C1012
265. P. Stankiewicz, and J.R. Lupski Structural variation in the human genome and its role in disease Annu Rev Med 61 2010 437 455
266. S. Stender, R. Frikke-Schmidt, A. Anestis, D. Kardassis, A.A. Sethi, and B.G. Nordestgaard Genetic variation in liver X receptor alpha and risk of ischemic vascular disease in the general population Arterioscler Thromb Vasc Biol 31 2011 2990 2996
267. J.C. Stevens New perspectives on the impact of cytochrome P450 3A expression for pediatric pharmacology Drug Discov Today 11 2006 440 445
268. M. Subramanian, V. Agrawal, D. Sandee, H.K. Tam, W.L. Miller, and T.S. Tracy Effect of P450 oxidoreductase variants on the metabolism of model substrates mediated by CYP2C9.1, CYP2C9.2, and CYP2C9.3 Pharmacogenet Genomics 22 2012 590 597
269. V. Sudhahar, S. Shaw, and J.D. Imig Epoxyeicosatrienoic acid analogs and vascular function Curr Med Chem 17 2010 1181 1190
270. J. Sun, X. Sui, J.A. Bradbury, D.C. Zeldin, M.S. Conte, and J.K. Liao Inhibition of vascular smooth muscle cell migration by cytochrome p450epoxygenase-derivedeicosanoids Circ Res 90 2002 1020 1027
271. G. Sun, J. Yan, K. Noltner, J. Feng, H. Li, and D.A. Sarkis SNPs in human miRNA genes affect biogenesis and function RNA 15 2009 1640 1651
272. S. Surapureddi, R. Rana, J.K. Reddy, and J.A. Goldstein Nuclear receptor coactivator 6 mediates the synergistic activation of human cytochrome P-450 2C9 by the constitutive androstane receptor and hepatic nuclear factor-4alpha Mol Pharmacol 74 2008 913 923
273. K.E. Swales, R. Moore, N.J. Truss, A. Tucker, T.D. Warner, and M. Negishi Pregnant X receptor regulates drug metabolism and transport in the vasculature and protects from oxidative stress Cardiovasc Res 93 2012 674 681
274. D. Szklarczyk, A. Franceschini, M. Kuhn, M. Simonovic, A. Roth, and P. Minguez The STRING database in 2011: Functional interaction networks of proteins, globally integrated and scored Nucleic Acids Res 39 2011 D561 D568
275. S. Takagi, M. Nakajima, K. Kida, Y. Yamaura, T. Fukami, and T. Yokoi MicroRNAs regulate human hepatocyte nuclear factor 4alpha, modulating the expression of metabolic enzymes and cell cycle J Biol Chem 285 2010 4415 4422
276. S. Takagi, M. Nakajima, T. Mohri, and T. Yokoi Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4 J Biol Chem 283 2008 9674 9680
277. W.J. Tamminga, J. Wemer, B. Oosterhuis, J. Weiling, B. Wilffert, and L.F. de Leij CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: Indications for oral contraceptive-related gender differences Eur J Clin Pharmacol 55 1999 177 184
278. P.H. Tate, and A.P. Bird Effects of DNA methylation on DNA-binding proteins and gene expression Curr Opin Genet Dev 3 1993 226 231
279. M.K. Tee, N. Huang, I. Damm, and W.L. Miller Transcriptional regulation of the human P450 oxidoreductase gene: Hormonal regulation and influence of promoter polymorphisms Mol Endocrinol 25 2011 715 731
280. K.N. Theken, Y. Deng, M.A. Kannon, T.M. Miller, S.M. Poloyac, and C.R. Lee Activation of the acute inflammatory response alters cytochrome P450 expression and eicosanoid metabolism Drug Metab Dispos 39 2011 22 29
281. K. Thelen, and J.B. Dressman Cytochrome P450-mediated metabolism in the human gut wall J Pharm Pharmacol 61 2009 541 558
282. M. Thörn, N. Finnström, S. Lundgren, A. Rane, and L. Lööf Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract Br J Clin Pharmacol 60 2005 54 60
283. T. Thum, and J. Borlak Gene expression in distinct regions of the heart Lancet 355 2000 979 983
284. T. Thum, V.J. Erpenbeck, J. Moeller, J.M. Hohlfeld, N. Krug, and J. Borlak Expression of xenobiotic metabolizing enzymes in different lung compartments of smokers and nonsmokers Environ Health Perspect 114 2006 1655 1661
285. A.H. Tolson, and H. Wang Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR Adv Drug Deliv Rev 62 2010 1238 1249
286. R.D. Travers, E.H. Reynolds, and B.B. Gallagher Variation in response to anticonvulsants in a group of epileptic patients Arch Neurol 27 1972 29 33
287. Y. Tsuchiya, M. Nakajima, S. Takagi, T. Taniya, and T. Yokoi MicroRNA regulates the expression of human cytochrome P450 1B1 Cancer Res 66 2006 9090 9098
288. N. Turan, S. Katari, C. Coutifaris, and C. Sapienza Explaining inter-individual variability in phenotype: Is epigenetics up to the challenge? Epigenetics 5 2010 16 19
289. J.P. Uetrecht Metabolism of drugs by leukocytes Drug Metabol Drug Interact 11 1994 259 282
290. T. Urano, T. Usui, M. Shiraki, Y. Ouchi, and S. Inoue Association of a single nucleotide polymorphism in the constitutive androstane receptor gene with bone mineral density Geriatr Gerontol Int 9 2009 235 241
291. B.L. Urquhart, R.G. Tirona, and R.B. Kim Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: Implications for interindividual variability in response to drugs J Clin Pharmacol 47 2007 566 578
292. E. Vreugdenhil, C.S. Verissimo, R. Mariman, J.T. Kamphorst, J.S. Barbosa, and T. Zweers MicroRNA 18 and 124a down-regulate the glucocorticoid receptor: Implications for glucocorticoid responsiveness in the brain Endocrinology 150 2009 2220 2228
293. D. Wang, Z. Jiang, Z. Shen, H. Wang, B. Wang, and W. Shou Functional evaluation of genetic and environmental regulators of p450 mRNA levels PLoS One 6 2011 e24900
294. V. Wauthier, R.K. Verbeeck, and P.B. Calderon The effect of ageing on cytochrome p450 enzymes: Consequences for drug biotransformation in the elderly Curr Med Chem 14 2007 745 757
295. D.J. Waxman, and M.G. Holloway Sex differences in the expression of hepatic drug metabolizing enzymes Mol Pharmacol 76 2009 215 228
296. J. Wójcikowski, and W.A. Daniel The brain dopaminergic system as an important center regulating liver cytochrome P450 in the rat Expert Opin Drug Metab Toxicol 5 2009 631 645
297. J. Wójcikowski, K. Gołembiowska, and W.A. Daniel The regulation of liver cytochrome p450 by the brain dopaminergic system Curr Drug Metab 8 2007 631 638
298. J. Wójcikowski, K. Gołembiowska, and W.A. Daniel Regulation of liver cytochrome P450 by activation of brain dopaminergic system: Physiological and pharmacological implications Biochem Pharmacol 76 2008 258 267
299. J. Wójcikowski, and W.A. Daniel The role of the nervous system in the regulation of liver cytochrome p450 Curr Drug Metab 12 2011 124 138
300. M. Wortham, M. Czerwinski, L. He, A. Parkinson, and Y.J. Wan Expression of constitutive Androstane receptor, hepatic nuclear factor 4 alpha, and P450 oxidoreductase genes determines interindividual variability in basal expression and activity of a broad scope of xenobiotic metabolism genes in the human liver Drug Metab Dispos 35 2007 1700 1710
301. H.G. Xie, S.L. Huang, Z.H. Xu, Z.S. Xiao, N. He, and H.H. Zhou Evidence for the effect of gender on activity of (S)-mephenytoin 4′-hydroxylase (CYP2C19) in a Chinese population Pharmacogenetics 7 1997 115 119
302. J. Xiong, D. Yu, N. Wei, H. Fu, T. Cai, and Y. Huang An estrogen receptor alpha suppressor, microRNA-22, is downregulated in estrogen receptor alpha-positive human breast cancer cell lines and clinical samples FEBS J 277 2010 1684 1694
303. C. Xu, C.Y. Li, and A.N. Kong Induction of phase I, II and III drug metabolism/transport by xenobiotics Arch Pharm Res 28 2005 249 268
304. L. Yang, Y. Li, H. Hong, C.W. Chang, L.W. Guo, and B. Lyn-Cook Sex differences in the expression of drug-metabolizing and transporter genes in human liver J Drug Metab Toxicol 3 2012 1 9
305. Z. Yang, and L. Wang Regulation of microRNA expression and function by nuclear receptor signaling Cell Biosci 1 2011 31
306. X. Yang, B. Zhang, C. Molony, E. Chudin, K. Hao, and J. Zhu Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver Genome Res 20 2010 1020 1036
307. A. Zadeh-Vakili, F. Ramezani Tehrani, M.S. Daneshpour, M. Zarkesh, N. Saadat, and F. Azizi Genetic polymorphism of vitamin D receptor gene affects the phenotype of PCOS Gene 515 2013 193 196
308. U.M. Zanger, and M. Schwab Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation Pharmacol Ther 138 2013 103 141
309. D.C. Zeldin Epoxygenase pathways of arachidonic acid metabolism J Biol Chem 276 2001 36059 36062
310. D.C. Zeldin, R.N. DuBois, J.R. Falck, and J.H. Capdevila Molecular cloning, expression and characterization of an endogenous human cytochrome P450 arachidonic acid epoxygenase isoform Arch Biochem Biophys 322 1995 76 86
311. D.C. Zeldin, J. Foley, S.M. Goldsworthy, M.E. Cook, J.E. Boyle, and J. Ma CYP2J subfamily cytochrome P450s in the gastrointestinal tract: Expression, localization, and potential functional significance Mol Pharmacol 51 1997 931 943
312. D.C. Zeldin, J. Foley, J. Ma, J.E. Boyle, J.M. Pascual, and C.R. Moomaw CYP2J subfamily P450s in the lung: expression, localization, and potential functional significance Mol Pharmacol 50 1996 1111 1117
313. F. Zhang, W. Gu, M.E. Hurles, and J.R. Lupski Copy number variation in human health, disease, and evolution Annu Rev Genomics Hum Genet 10 2009 451 481
314. Y. Zhang, K. Klein, A. Sugathan, N. Nassery, A. Dombkowski, and U.M. Zanger Transcriptional profiling of human liver identifies sex-biased genes associated with polygenic dyslipidemia and coronary artery diseases PLoS One 6 2011 e23506
315. J. Zhang, P. Kuehl, E.D. Green, J.W. Touchman, P.B. Watkins, and A. Daly The human pregnane X receptor: Genomic structure and identification and functional characterization of natural allelic variants Pharmacogenetics 11 2001 555 572
316. S.Y. Zhang, S. Surapureddi, S. Coulter, S.S. Ferguson, and J.A. Goldstein 2012. Human CYP2C8 is post-transcriptionally regulated by microRNAs 103 and 107 in human liver Mol Pharmacol 82 2012 529 540
317. J.J. Zhao, J. Lin, H. Yang, W. Kong, L. He, and X. Ma MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer J Biol Chem 283 2008 31079 31086
318. S. Zhou, Y. Gao, W. Jiang, M. Huang, A. Xu, and J.W. Paxton Interactions of herbs with cytochrome P450 Drug Metab Rev 35 2003 35 98
319. S.F. Zhou, J.P. Liu, and B. Chowbay Polymorphism of human cytochrome P450 enzymes and its clinical impact Drug Metab Rev 41 2009 89 295
320. T. Zhou, Y. Zhang, A. Macchiarulo, Z. Yang, M. Cellanetti, and E. Coto Novel polymorphisms of nuclear receptor SHP associated with functional and structural change J Biol Chem 285 2010 24871 24881
321. S.F. Zhou, Z.W. Zhou, L.P. Yang, and J.P. Cai Substrates, inducers, inhibitors and structure-activity relationship of human cytochrome P450 2C9 and implication in drug development Curr Med Chem 16 2009 3480 3675
322. Y. Zhu, E.B. Schieber, J.C. McGiff, and M. Balazy Identification of arachidonate P-450 metabolites in human platelet phospholipids Hypertension 25 1995 854 859
323. M. Zorc, D.J. Skok, I. Godnic, G.A. Calin, S. Horvat, and Z. Jiang Catalog of microRNA seed polymorphisms in vertebrates PLoS One 7 2012 e30737
324. B.N. Zordoky, and A.O. El-Kadi Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases Pharmacol Ther 125 2010 446 463